NFKB1 and lung carcinoma: Although the gene remains largely untargeted, pioneering studies have elucidated the signaling cascades originating in lung cancer cells from KRAS activating mutations and have provided the medical community with novel therapeutic targets, such as the combined KRAS/NF-κB inhibition [25].